Holen Sie sich die Stockscreener-App
18.43
0.73%
-0.1382
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Arvinas terminates lease agreement, frees up future liabilities - Investing.com
Arvinas Holding Company Adjusts Real Estate Strategy - TipRanks
Assenagon Asset Management S.A. Buys 777 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
Arvinas Repeat Insider Selling Not A Positive Indicator - Simply Wall St
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025 - The Motley Fool
Arvinas, Inc. (NASDAQ:ARVN) Receives $63.50 Average PT from Analysts - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains? - MSN
Arvinas (NASDAQ:ARVN) Sets New 12-Month LowShould You Sell? - MarketBeat
Arvinas stock touches 52-week low at $17.35 amid market challenges - Investing.com Australia
Arvinas outlines 2025 clinical trial plans for breast cancer drug By Investing.com - Investing.com Australia
Arvinas Announces Updates on Clinical Trials Progress - TipRanks
Arvinas outlines 2025 clinical trial plans for breast cancer drug - Investing.com India
Arvinas Updates Guidance for First- and Second-Line Phase 3 - GlobeNewswire
Arvinas Plans Two Phase 3 Trials for Breakthrough Breast Cancer Drug, Expands Pipeline for 2025 - StockTitan
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update - Business Upturn
Metastatic Prostate Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion Corporation - Barchart
Metastatic Prostate Cancer Market to Expand Significantly - openPR
JPMorgan Chase & Co. Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
JPMorgan Chase & Co. Increases Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas (NASDAQ:ARVN) Trading 9.2% HigherHere's Why - MarketBeat
How To Trade (ARVN) - Stock Traders Daily
March 21st Options Now Available For Arvinas (ARVN) - Nasdaq
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Increases By 6.5% - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Increase in Short Interest - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Receives $63.50 Consensus Target Price from Brokerages - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Arvinas (NASDAQ:ARVN) Shares Down 3.3%Should You Sell? - MarketBeat
Arvinas' Vepdegestrant: Why The Data May Not Hold Up (NASDAQ:ARVN) - Seeking Alpha
Barclays PLC Purchases 80,984 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Long Term Trading Analysis for (ARVN) - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by State Street Corp - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Down 6.2%Time to Sell? - MarketBeat
New Haven-based Arvinas to expand Science Park footprint; renews leases - Hartford Business Journal
New Haven-based Arvinas to expand Science Park footprint; extends leases - Hartford Business Journal
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results By Investing.com - Investing.com Australia
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results - Investing.com
Metastatic Prostate Cancer Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Merck Sharp, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis - Barchart
Arvinas secures expanded New Haven premises until 2029 By Investing.com - Investing.com South Africa
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Increases By 5.6% - MarketBeat
Arvinas stock touches 52-week low at $21.17 amid market challenges - Investing.com Canada
(ARVN) Trading Advice - Stock Traders Daily
0.81%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):